

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
22 December 2022 (22.12.2022)




(10) International Publication Number  
**WO 2022/266318 A4**

- (51) **International Patent Classification:**  
*A61K 31/33* (2006.01) *A61K 31/4164* (2006.01)  
*A61K 31/41* (2006.01) *A61K 31/00* (2006.01)
- (21) **International Application Number:**  
PCT/US2022/033786
- (22) **International Filing Date:**  
16 June 2022 (16.06.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
63/211,320 16 June 2021 (16.06.2021) US  
63/236,972 25 August 2021 (25.08.2021) US  
63/263,556 04 November 2021 (04.11.2021) US  
63/264,052 15 November 2021 (15.11.2021) US
- (71) **Applicant: ACURX PHARMACEUTICALS, INC.**  
[US/US]; 259 Liberty Ave., Staten Island, New York 10305 (US).
- (72) **Inventor: GAREY, Kevin;** 311 W. 24th Street, Houston, Texas 77018 (US).
- (74) **Agent: YELLIN, Deborah;** Crowell & Moring LLP, 1001 Pennsylvania Ave NW-Floor 10, United States of America, Washington, District of Columbia 20004 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) **Title:** USE OF IBEZAPOLSTAT TO PROMOTE MICROBIOME HEALTH

Fig. 1

Alpha diversity changes during the course of therapy



(57) **Abstract:** The invention relates to methods of using ibezapolstat to increase the health of the gut microbiome. The invention provides methods of simultaneously treating *C. difficile* infections while at the same time reducing the likelihood of or preventing the recurrence of *C. difficile* infection. The invention also provides methods of increasing the health of the gut microbiome by increasing the number of Actinobacteria and/or Firmicutes in the gut.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *with amended claims (Art. 19(1))*

**(88) Date of publication of the international search report:**

26 January 2023 (26.01.2023)

**Date of publication of the amended claims:**

16 March 2023 (16.03.2023)